Karin Teppert, Isabella Elias Yonezawa Ogusuku, Caroline Brandes, Vera Herbel, Nora Winter, Niels Werchau, Svetlana Khorkova, Christian Wöhle, Nojan Jelveh, Kevin Bisdorf, Boris Engels, Thomas Schaser, Kathleen Anders, Annette Künkele, Dominik Lock
Acute myeloid leukemia (AML), a fast-progressing hematological malignancy affecting myeloid cells, is typically treated with chemotherapy or hematopoietic stem cell transplantation. However, approximately half of the patients face relapses and 5-year survival rates are poor. With the goal to facilitate dual-specificity, boosting anti-tumor activity, and minimizing the risk for antigen escape, this study focused on combining chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies. CAR'TCR-T cells, co-expressing a CD33-CAR and a transgenic dNPM1-TCR, revealed increased and prolonged anti-tumor activity in vitro , particularly in case of low target antigen expression...
June 20, 2024: Mol Ther Oncol